Abstract
Introduction: Alzheimer's disease is known to be a chronic disease, with an estimated prevalence of about 10-30%, considering the population over 60 years of age. Most patients with this disorder (> 95%) present the sporadic form, being characterized by a late onset (80-90 years of age), and it is the consequence of the failure to clear the amyloid-β (Aβ) peptide from the interstices of the brain. Significant numbers of genetic risk factors for the sporadic disease have been researched. Some existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease- modifying therapies. In this line, a complementary strategy based on repositioning drugs which are approved for the treatment of other disorders could be interesting. It is noteworthy the fact that some clinical trials indicate that several classes of drugs own potent and beneficial effects on the Alzheimer's disease treatment. In this present work, we present the details and evaluation of these alternative treatments. It has highlighted several compounds with relevant evidence for this purpose, which deserves further investigation to clarify optimal treatment conditions in the clinical trials of patients with Alzheimer's disease.
Keywords: Alzheimer’s disease, neurodegeneration, drug repositioning, tau protein, amyloid-β peptide, pharmacophores.
Current Alzheimer Research
Title:Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives
Volume: 15 Issue: 12
Author(s): Alexandre A. de Castro, Elaine F.F. da Cunha, Ander F. Pereira, Flavia V. Soares, Daniel H.S. Leal, Kamil Kuca and Teodorico C. Ramalho*
Affiliation:
- Department of Chemistry, Federal University of Lavras, Lavras/MG, 37200-000,Brazil
Keywords: Alzheimer’s disease, neurodegeneration, drug repositioning, tau protein, amyloid-β peptide, pharmacophores.
Abstract: Introduction: Alzheimer's disease is known to be a chronic disease, with an estimated prevalence of about 10-30%, considering the population over 60 years of age. Most patients with this disorder (> 95%) present the sporadic form, being characterized by a late onset (80-90 years of age), and it is the consequence of the failure to clear the amyloid-β (Aβ) peptide from the interstices of the brain. Significant numbers of genetic risk factors for the sporadic disease have been researched. Some existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease- modifying therapies. In this line, a complementary strategy based on repositioning drugs which are approved for the treatment of other disorders could be interesting. It is noteworthy the fact that some clinical trials indicate that several classes of drugs own potent and beneficial effects on the Alzheimer's disease treatment. In this present work, we present the details and evaluation of these alternative treatments. It has highlighted several compounds with relevant evidence for this purpose, which deserves further investigation to clarify optimal treatment conditions in the clinical trials of patients with Alzheimer's disease.
Export Options
About this article
Cite this article as:
de Castro A. Alexandre, da Cunha F.F. Elaine , Pereira F. Ander , Soares V. Flavia, Leal H.S. Daniel , Kuca Kamil and Ramalho C. Teodorico *, Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives, Current Alzheimer Research 2018; 15 (12) . https://dx.doi.org/10.2174/1567205015666180813150703
DOI https://dx.doi.org/10.2174/1567205015666180813150703 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of ER Stress-Induced Apoptosis in Neurodegeneration
Current Alzheimer Research Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents
Current Drug Targets Selective Estrogen Receptor Modulators (SERMs): Effects on Multiple Organ Systems
Current Medicinal Chemistry The Transcriptome in Blood: Challenges and Solutions for Robust Expression Profiling
Current Molecular Medicine How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design The Concept of Protein Mosaics: Physiological Role and Relevance for Prion Disease
Current Proteomics Biological Insight, High-Throughput Datasets and the Nature of Neuro-Degenerative Disorders
Current Drug Metabolism Neuronal Nicotinic Acetylcholine Receptors - Targets for the Development of Drugs to Treat Cognitive Impairment Associated with Schizophrenia and Alzheimers Disease
Current Topics in Medicinal Chemistry Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Characterization of Lin-ve CD34 and CD117 Cell Population Reveals an Increased Expression in Bone Marrow Derived Stem Cells
Current Neurovascular Research Dissecting the Diverse Actions of Pro- and Mature Neurotrophins
Current Alzheimer Research Determination of Parameters of Oxidative Stress in vitro Models of Neurodegenerative Diseases-A Review
Current Clinical Pharmacology The Urocortins: Mechanisms of Cardioprotection and Therapeutic Potential
Mini-Reviews in Medicinal Chemistry A Review of the Psychometric Properties of the CRAFFT Instrument: 1999-2010
Current Drug Abuse Reviews Selenium Influence in the Poultry Immune Response - Review
Recent Patents on Food, Nutrition & Agriculture Sulfonamide Agents for Treatment of Staphylococcus MRSA and MSSA Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Recent Trends in Nanotechnology-Based Drugs and Formulations for Targeted Therapeutic Delivery
Recent Patents on Inflammation & Allergy Drug Discovery Retraction Notice: Protein Identification in Sub Proteome Fractions of Breast Cancer Cells by OFFGEL-IEF and iTRAQ Labeling
Current Proteomics Towards an Experimental and Systems Biology Framework for Cancer Cell Therapeutics
Current Bioinformatics